Fortrea appoints Tracy Krumme as new head of investor relations

DURHAM, N.C. - Fortrea (NASDAQ:FTRE), a contract research organization (CRO) with annual revenue of $2.69 billion, announced Tuesday the appointment of Tracy Krumme as senior vice president of investor relations, replacing Hima Inguva who is leaving to pursue other opportunities. According to InvestingPro data, the company’s stock has shown significant volatility recently, with a strong return over the last month despite a challenging year.

Krumme will report to Chief Financial Officer Jill McConnell and will be responsible for the company’s global investor relations strategy while serving as the primary liaison to the investment community.

The new appointee brings more than 30 years of investor relations and capital markets experience to the role, with specific expertise in the CRO, life sciences, and healthcare sectors. She previously led investor relations at PPD, a CRO that was acquired by Thermo Fisher Scientific, where she worked with Fortrea’s current CEO Anshul Thakral.

Her career also includes investor relations leadership positions at Galderma, Nuance Communications, Bitfarms, Luxoft, and NCR Corporation. Earlier in her career, Krumme worked as an equity research analyst at Sandler O’Neill & Partners and held corporate finance roles at Prudential Securities and Kidder, Peabody International.

Fortrea provides phase I-IV clinical trial management, clinical pharmacology, and consulting services to biopharmaceutical, biotechnology, medical device, and diagnostic companies across approximately 100 countries.

The announcement was made in a company press release statement.

In other recent news, Fortrea Holdings Inc. has made several notable announcements. The company reported the approval of significant changes to its executive compensation framework, including an amendment to its 2023 Omnibus Incentive Plan, which now includes an increase in share count by 6.5 million shares and sets minimum vesting periods. Additionally, Fortrea has adopted a limited-duration stockholder rights plan, effective immediately, to address significant dislocation in its stock price and interest from third parties. This plan is set to expire on June 10, 2026, unless terminated earlier.

In a strategic move, Fortrea has partnered with Emery Pharma to provide testing for 1-methyl-4-nitrosopiperazine impurities in rifampin, ensuring compliance with FDA guidelines. Furthermore, the company announced the appointment of Anshul Thakral as its new Chief Executive Officer, effective August 4, 2025, succeeding Interim CEO Peter M. Neupert. These developments reflect Fortrea’s ongoing efforts to align executive interests with shareholders, protect shareholder value, and enhance its leadership team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.